dinogreeves
7 days ago
"Good afternoon Bulls, this afternoon, I had an appointment with my broker and banking analyst that I have known for many years, and for whom I really trust, for different things for me and I had previously asked him a question concerning the company $VCNX for which he took the time today, to explain to me, and to summarize for me, as an analyst, the bottom of his thinking, and I want to share with you, because whether you believe me or not, it is your choice, but I wanted to share it with you because this analyst who takes care of everything that is brokerage, stock market at the level of his bank informed me, that they have also had an eye on the company $VCNX for some time of what it is doing and of all this good progress that it has had to date, so from what I could see there are many institutions and banks that follow this title very closely too"
tw0122
4 weeks ago
On October 7, 2024, the Company received a letter from the Nasdaq Listing Staff stating that the Company had not regained compliance with the Equity Standard or the Alternatives Standards and that, as a result, unless the Company timely requests an appeal of this determination to a Nasdaq Hearings Panel, Nasdaq would move to suspend trading of the Company’s common stock and to have the Company’s securities delisted from the Nasdaq Capital Market. The Company intends to timely appeal the determination, which will automatically stay any suspension or delisting action pending the Hearings Panel’s decision and the expiration of any additional extension period granted by the Hearings Panel following the hearing. As a result, the Company’s common stock is expected to remain listed on the Nasdaq Capital Market through at least that time. However, there can be no assurance that the Hearings Panel will grant the Company’s request for continued listing or that the Company will be able to demonstrate compliance with the Equity Standard or the Alternative Standards within any additional compliance period that may be gra
tw0122
4 weeks ago
$5.63 offering of 1,067,492 shares of common stock (the “Existing Warrants”) at the reduced exercise price of $5.636 per share, resulting in the issuance of 827,483 shares and the pre-funding of 240,009 shares.
In consideration for the immediate exercise of the warrants for cash and the payment of an additional $0.125 per new warrant, the exercising holders will also receive new warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The new warrants will be exercisable into an aggregate of up to 1,601,238 shares of common stock, at an exercise price of $5.636 per share (priced at-the-market under the rules of the Nasdaq Stock Market) and will expire five years after issuance.
The gross proceeds to the Company from the exercise of the Existing Warrants together with the sale of the new warrants is expected to be approximately $6.2 million. The closing of the transaction is expected to occur on or about September 18, 2024, subject to satisfaction of customary closing conditions.
Participants in the transaction include entities affiliated with by Maurice Zauderer, President and CEO of the Company, and Albert D. Friedberg, Chairman of the Company’s board of directors. These entities accounted for approximately 51% of the securities in the transaction.
Roth Capital Partners is acting as the Company’s financial advisor for this transaction.
An aggregate of 768,268 of the shares of common stock issuable upon exercise of the Existing Warrants are registered for sale or resale pursuant to effective registration statements. The warrants offered in the private placement have not been registered under the Securities Act or applicable state securities laws. The Company has agreed to file a resale registration statement with the SEC to register the resale of the shares of common stock issuable upon exercise of the new warrants.
TheFinalCD
9 months ago
Private Placement 5,103,622 $0.73 5,103,622 $3,700,126 Insiders 2024-2-7 8:00
Underwritten S-1 9,000,000 $1.00 9,000,000 $9,000,000 AGP Directors 2023-9-28 21:00
Private Placement 3,733,973 $0.16 0 $582,500 CEO 2023-9-20 0:00
Private Placement 3,140,095 $0.21 0 $650,000 E&R Ventures, 110 Ventures, Ample Investing 2023-8-18 0:00
Private Placement 7,908,516 $0.37 0 $2,959,999 Chairman, 3i, AIGH, Lublin 2023-5-15 0:00
Private Placement 4,975,608 $0.41 0 $2,039,999 Maurice Zauderer, CEO, Chairman 2023-4-3 8:30
Private Placement 7,142,496 $0.53 $3,780,523 2022-11-18 0:00
Private Placement 5,945,943 $1.11 0 $6,599,997 Jefferies, Barclays, Wedbush, HC Wainwright 2022-1-27 16:15
Convertible 917,928 $9.41 $8,640,000 3i 2020-7-31 0:00
Private Placement 1,126,760 $3.55 $3,999,998 2020-7-10 0:00
$vcnx .70
also 2 form 4's tonight
https://ih.advfn.com/stock-market/NASDAQ/vaccinex-VCNX/stock-news/93249354/form-4-statement-of-changes-in-beneficial-owners
https://ih.advfn.com/stock-market/NASDAQ/vaccinex-VCNX/stock-news/93249369/form-4-statement-of-changes-in-beneficial-owners